AIP
MRNA icon

Almanack Investment Partners’s Moderna MRNA Stock Holding History

Almanack Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,361
Closed -$755K – 187
2024
Q2 		$755K Buy
+6,361
New +$805K 0.13% 91
2023
Q2 		– Sell
-1,480
Closed -$227K – 173
2023
Q1 		$227K Sell
1,480
-3,650
-71% -$602K 0.04% 151
2022
Q4 		$921K Sell
5,130
-9,448
-65% -$1.54M 0.2% 56
2022
Q3 		$1.72M Buy
+14,578
New +$2.21M 0.34% 41
2022
Q2 		– Sell
-2,379
Closed -$410K – 493
2022
Q1 		$410K Buy
2,379
+737
+45% +$124K 0.04% 296
2021
Q4 		$417K Buy
1,642
+873
+114% +$255K 0.03% 294
2021
Q3 		$296K Buy
+769
New +$284K 0.03% 377

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Almanack Investment Partners's MRNA Position: Q3 2024 in Review

Almanack Investment Partners sold out of Moderna (MRNA) in Q3 2024, closing a stake of 6,361 shares — an estimated $755K sold.

Almanack Investment Partners first reported a position in MRNA in Q3 2021 and held it in 7 quarters. The position peaked at $1.72M in Q3 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Almanack Investment Partners reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Almanack Investment Partners sold 6,361 Moderna shares in Q3 2024, an estimated $755K.
  • Almanack Investment Partners first reported a position in Moderna in Q3 2021 and held it in 7 quarters.
  • Almanack Investment Partners's Moderna position peaked at $1.72M in Q3 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Almanack Investment Partners's 13F filing for Q3 2024, filed 31 Oct 2024.